ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health
Annelies Boonen(Maastricht University), Désirée van der Heijde(Leiden University Medical Center), Nenad Kostanjsek(World Health Organization), Gerold Stucki(University of Lucerne), Jürgen Braun(Center for HIV and Hepatogastroenterology), Walter P. Maksymowych(University of Alberta), Alarcos Cieza(World Health Organization - Pakistan), I.E. van der Horst Bruinsma(Amsterdam UMC Location VUmc), Feng Huang(Guangxi Medical University)
Cited by 138
Related Papers
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
|The Lancet|2004|1.8k
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
|Annals of the Rheumatic Diseases|2017|675
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two‐year clinical and radiographic results from the TEMPO study, a double‐blind, randomized trial
|Arthritis & Rheumatism|2006|542
EULAR definition of difficult-to-treat rheumatoid arthritis
|Annals of the Rheumatic Diseases|2020|538
Validation of the "World Health Organization Disability Assessment Schedule, WHODAS-2" in patients with chronic diseases
|Health and Quality of Life Outcomes|2010|439